Table 2.
Characterization of patients with missing time trade-off data at baseline or follow-up
| Baseline factor | Patients without baseline TTO data (N=29) |
Patients with baseline who survived without follow-up TTO (N=62) |
Patients with baseline and TTO at 3 and/or 6 months (N=287) |
|---|---|---|---|
| Male, % | 79 | 68 | 75 |
| Minority, % | 45 | 47 | 39 |
| LVEF, % | 20 (15, 25) | 19 (15, 20) | 20 (15, 25) |
| SBP, mm Hg | 98 (90, 110) | 101 (93, 113) | 106 (95, 118) |
| BUN, mg/dl | 37 (26, 54) | 26 (17, 41) | 27 (19, 38) |
| BNP, pg/ml | 976 (477, 1952) | 585 (257, 1042) | 511 (193, 1044) |
| 6-min walk, ft | 120 (0, 530) | 26 (0, 531) | 444 (20, 854) |
| JVP, cm, % | |||
| <8 | 10 | 12 | 8 |
| 8–12 | 28 | 40 | 41 |
| 12–16 | 41 | 17 | 31 |
| >16 | 21 | 12 | 20 |
| Edema, % | |||
| 0–1+ | 65 | 64 | 68 |
| 3–4+ | 17 | 11 | 11 |
| Freedom from worst | 40 (20, 55) | 30 (20, 50) | 35 (20, 50) |
| symptom, (0–100, 100 best) | |||
| Global score | 35 (28, 52) | 40 (30, 50) | 40 (30, 60) |
| MLHF score | 75 (66, 82) | 73 (58, 84) | 76 (65, 87) |
Median (25th, 75th) unless otherwise indicated.